Result
Safety · Primary, pre-specified · Efficacy
Effect as reported: [object Object]
Location in the source: results
Part 2 - AXER-204 - 200 mg: 14
Study
NCT03989440/brief_summary
human Human · Open label · Uncontrolled · Outside our vocabulary · AIS not reported
Participants actually studied: 52
No dataNothing has been recorded here yet. This is not a zero.
What this result says about which claim
- Partially supports — Intrathecal administration of a soluble Nogo receptor decoy protein is well tolerated after spinal cord injury and does not increase the incidence of serious adverse events.
Part 2 - AXER-204 - 200 mg: 14